Repligen (RGEN) Tops Q4 EPS by 5c; offers guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
EPS Growth %: 0.0%
Financial Fact:
Total operating expenses: 20.93M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Total operating expenses: 20.93M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.49, $0.05 better than the analyst estimate of $0.44. Revenue for the quarter came in at $197.91 million versus the consensus estimate of $192.89 million.
GUIDANCE:
Repligen sees FY2026 EPS of $1.93-$2.01, versus the consensus of $2.07. Repligen sees FY2026 revenue of $810-840 million, versus the consensus of $823.9 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
